-
Your selected country is
Italy
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
CD103 FITC
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.
Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.
CD103 is intended for in vitro diagnostic use in the identification of cells expressing CD103 antigen, using a BD FACS™ brand flow cytometer. The flow cytometer must be equipped to detect light scatter and the appropriate fluorescence, and be equipped with appropriate analysis software (such as BD CellQuest™ or BD LYSYS™ II software) for data acquisition and analysis. Refer to your instrument user’s guide for instructions.
Development References (22)
-
Babusikova O, Tomova A, Kusenda J, Gyarfas J. Flow cytometry of peripheral blood and bone marrow cells from patient with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment. Neoplasma. 2001; 48:350-357. (Biology).
-
Braylan RC, Orfao A, Borowitz MJ, Davis BH. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. Clin Cytometry. 2001; 46:23-27. (Biology).
-
Brew R, West DC, Burthem J, Christmas SE. Expression of the human mucosal lymphocyte antigen, HML-1 by T cells activated with mitogen or specific antigen in vitro. Scan J Immunol. 1995; 41:553-562. (Biology).
-
Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
-
Cepek K, Wong D, Brenner M, Springer T. Schlossman S, Boumsell L, Gilks W, et al Leucocyte Typing V: White Cell Differentiation Antigens, ed. New York, NY: 1995:1666-1667.
-
Cerf-Benussan N, Jarry A, Brousse N, Lisowska-Grospierre B, Guy-Grand D, Griscelli C. A monoclonal antibody (HML-1) defining a novel membrane molecule present on human intestinal lymphocytes. Eur J Immunol. 1987; 17:1279–1285. (Biology).
-
Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes: Approved Guideline. NCCLS document H42-A. 1998. (Biology).
-
Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Rothe G, Schmitz G. Leukemia. 1996; 10:877-895. (Biology).
-
Cornfield DB, Mitchell Nelson DM, Rimsza LM, Moller-Patti D, Braylan RC. The diagnosis of hairy cell leukemia can be established by flow cytometric analysis of peripheral blood, even in patients with low levels of circulating malignant cells. Am J Hematol. 2001; 67:223-226. (Biology).
-
Hadley GA, Rostapshova EA, Gomolka DM, et al. Regulation of the epithelial cell-specific integrin, CD103, by human CD8+ cytolytic T lymphocytes. Transplantation. 1999; 67:1418–1425. (Biology).
-
Hassan IB, Hagberg H, Sundström C. Immunophenotype of hairy-cell leukemia. Eur J Haematol. 1990; 45:172-176. (Biology).
-
Jackson AL, Warner NL. Rose NR, Friedman H, Fahey JL, ed. Manual of Clincial Laboratory Immunology, Third Edition. Washington DC: American Society for Microbiology; 1986:226-235.
-
Kruschwitz M, Fritzsche G, Schwarting R, et al. Ber-ACT8: new monoclonal antibody to the mucosa lymphocyte antigen. J Clin Pathol. 1991; 44(8):636-645. (Biology). View Reference
-
Lohmeyer J, Friedrish J, Grimminger F, et al. Expression of mucosa-related integrin αEβ7 on alveolar T cells in interstitial lung diseases. Clin Exp Immunol. 1999; 116:340-346. (Biology).
-
Micklem KJ, Dong Y, Willis A, et al. HML-1 antigen on mucosa-associated T cells, activated cells, and hairy leukemic cells is a new integrin containing the β7 subunit. Am J Pathol. 1996; 3:30-36. (Biology).
-
Moldenhauer G, Mielke B, Dörken B, Schwartz-Albiez R, Möller P. Identity of HML-1 antigen on intestinal intraepithelial T cells and of B-ly7 antigen on hairy cell leukaemia. Scand J Immunol. 1990; 32:77–82. (Biology).
-
Möller P, Mielke B, Moldenhauer G. Monoclonal antibody HML-1, a marker for intraepithelial T cells and lymphomas derived thereof, also recognizes hairy cell leukemia and some B-cell lymphomas. Am J Pathol. 1990; 136:509–512. (Biology).
-
NCCLS document. 2001. (Biology).
-
Parker CM, Cepek KL, Russell GJ, et al. A family of beta 7 integrins on human mucosal lymphocytes. Proc Natl Acad Sci U S A. 1992; 89(5):1924-1928. (Biology). View Reference
-
Rihs S, Walker C, Virchow Jr JC, et al. Differential expression of αEβ7 integrins on bronchoalveolar lavage T lymphocyte subsets: regulation by α4β1-integrin crosslinking and TGF-β. Am J Respir Cell Mol Biol. 1996; 15:600-610. (Biology).
-
San Miguel JF, Vidriales MB, Ocio E, et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol. 2003; 30:187-195. (Biology).
-
Stelzer GT, Marti G, Hurley A, McCoy PJ, Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997; 30:214-230. (Biology).
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For In Vitro Diagnostic Use.
23-22942-00
Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.